FDA
-
-
-
-
-
-
-
Delcath Systems reports preliminary 2025 revenue of $85.2 million
-
-
-
-
-
-
-
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
-
-
-
-
-
-
-
Delcath Systems to Host Third Quarter 2025 Earnings Call
-
-
-
-
-
-
-
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Delcath Systems to Host Second Quarter 2025 Earnings Call
-
-
-
-
-
-
-
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
-
-
-
-
-
-
-
Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

